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ABSTRACT
Bisphosphonates inhibit osteoclasts activity and therefore reduce bone resorption. The main application of bispho-
sphonates in patients with cancer involves treatment of hypercalcemia, prevention of cancer treatment-induced 
bone loss, and decrease of the risk of skeletal-related events in patients with breast cancer or prostate cancer and 
bone metastases. For some time now there has been an increasing amount of data indicating that treatment with 
bisphosphonates improves survival of patients with early breast cancer. The activity is restricted to postmenopausal 
women or premenopausal patients whose treatment involves gonadotropin agonist.
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Introduction
Bisphosphonates (BPs) are synthetic analogues of 
naturally existing pyrophosphate. The first bisphos-
phonate was developed in the 19th century [1]. It was 
primarily used in the chemical industry as an anticor-
rosive and anti-scaling agent. The ability of BPs to slow 
down a breakout of hydroxyapatite was discovered in 
the 1860s. In 1969 the first BP was used in medicine in 
a man with myositis ossificans.
BPs differ in chemical structure — they are divided 
into two classes: BPs of the first generation (or simple 
BPs), which do not contain nitrogen; and nitrogen-con-
taining BPs of the second or third generation. This 
classification correlates with the ability of BPs to inhibit 
bone resorption and is related to different mechanisms 
of action (Tab. 1).
Basic mechanism by which BPs inhibit bone re-
sorption results from their very high affinity to mineral 
components of bone and binding with hydroxyapatite 
crystals. BPs are captured by bones selectively and 
built in areas of the bone’s active rebuilding. The 
remaining BPs are excreted by urine. The amount of 
BPs that bind to bones relates mainly to the intensity 
of bone turnover, the route of administration, and the 
affinity of BPs to react with bone structure. Activated 
osteoclasts brake down the bone-matrix on the surface 
of bones, and therefore induce the release of bone-de-
rived constituents, including BPs, which are absorbed 
by osteoclasts. The accumulation of end products of 
BP metabolism in osteoclasts induces its apoptosis and 
therefore inhibits bone resorption [2]. The newer BPs 
have also an ability (in vitro) to inhibit proliferation, in-
vasion, and migration of cancer cells, to induce apoptosis 
of cancer cells, to inhibit neoangiogenesis, to activate 
of T gd lymphocytes, and to modulate macrophage and 
osteoblast activity [3].
The most important areas of BP usage in onco-
logy are:
 — treatment of hypercalcaemia (this article does not 
elaborate on that);
 — inhibition of cancer treatment-induced bone loss 
(CTIBL);
 — reduction of the risk of skeletal-related events 
(SRE) or delay of their occurrence in patients with 
bone metastases;
 — reduction of the risk of cancer recurrence and mor-
tality after definite treatment.
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Table 1. Classification of bisphosphonates
Subclass Generation Drug Force Mechanism of action






















BPs in patients with breast cancer
A prevention of CTIBL
In premenopausal women diagnosed with breast 
cancer, systemic treatment can induce a secondary 
loss of ovarian function (e.g. after chemotherapy) or 
may directly suppress ovarian function by hormonal 
blockage with luteinising hormone releasing hormone 
analogue (aLHRH). Long-lasting oestrogen deficiency 
has a profound effect on bone health. In women in 
whose treatment induced premature menopause, both 
permanent (after chemotherapy) or temporary (during 
aLHRH treatment), the assessment of bone fracture risk 
by bone densitometry is recommended. Furthermore, 
a concentration of serum calcium, 25-OH-vitamin 
D, or parathyroid hormone as secondary causes of 
osteoporosis should be evaluated. It is recommended 
to advise a calcium-enriched diet (1000 mg every day), 
vitamin D (1000–2000 units every day), and to change 
lifestyle habits by taking more weight-bearing exercise, 
quitting smoking, and reducing alcohol consumption. 
In cases when bone-mineral density is reduced (e.g. 
T-score < –2) a therapy of BP should be considered [4]. 
Clodronate and risedronate are active in the prevention 
of bone resorption in premenopausal women; however, 
most data come from trials with zoledronic acid (4 mg 
intravenously every six months). Zoledronic acid is 
therefore recommended to prevent bone loss.
In postmenopausal women treated with aromatase 
inhibitor (IA) bone health should be monitored for 
risk of fracture by bone densitometry and other diag-
nostic tools, e.g. the FRAX (Fracture Risk Assessment 
Tool) algorithm designed by the WHO (World Health 
Organisation), which unfortunately does not include 
antineoplastic treatment as a specific risk factor of bone 
loss. General recommendations involve supplementa-
tion of calcium and vitamin D, as well as a change in 
lifestyle (as mentioned above). Anti-resorptives should 
be considered in patients with T-score < –2 or in those 
having at least two risk factors of bone fracture, e.g. 
age < 65, T-score < –1.5, active cigarette smoking, BMI 
(body mass index) < 24, long-term (> 6 months) gluco-
corticoid consumption, bone fractures in age > 50 years, 
or positive family history of osteoporosis [4]. In women 
with cancer treated with IA, some agents have demon-
strated activity in reducing the risk of CTIBL (Tab. 2) 
[5–10]. The activity of denosumab is not the subject of 
this article.
Therapy with BP in patients with breast cancer and 
bone metastases
In 2012 a Cochrane database meta-analysis revealed 
that therapy with BPs compared with no BPs in women 
with breast cancer and bone metastases reduces the 
risk of SRE by 15% [RR (relative risk) 0.85; 95% Cl 
0.77–0.94; p = 0.001], increases the median time to oc-
currence of SRE, decreases bone pain, and improves 
quality of life [11]. Overall survival is not affected by 
the therapy. Either ibandronate (oral and intravenous), 
clodronate, pamidronate, or zoledronic acid were effec-
tive. Reduction of the risk of SRE varied from 14% for 
oral ibandronate, 23% for intravenous pamidronate, 
up to 41% for zoledronic acid; however, those differ-
ences should not influence clinical practice. It should be 
emphasised that pamidronate and zoledronate are the 
only intravenous BPs whose clinical effectiveness has 
been proven in many end-points.
In a phase III non-inferiority trial carried out on 
breast-cancer patients with bone metastases and on 
Table 2. Anti-resorptive drugs for the prevention of CTIBL 
in postmenopausal women with breast cancer
Bisphosphonates Ibandronate 150 mg p.o. every month
Clodronate 1600 mg p.o. every day
Risedronate 35 mg p.o. every week
Alendronate 70 mg p.o. every week
Zoledronic acid 4 mg i.v. every 6 months
Anti-RANKL Denosumab 60 mg s.c. every 6 months
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patients with multiple myeloma, pamidronate had 
similar efficacy to zoledronic acid [12]. In another phase 
III non-inferiority ZICE trial, the effectiveness of oral 
ibandronate was inferior to zoledronic acid in reduc-
ing the risk of SRE [hazard ratio (HR) 1.15; 95% Cl 
0.967–1.362; p = 0.017]; however, the ability to delay 
the first SRE was similar [13]. 
The influence of BPs on a risk of SRE seems to be re-
lated to duration of BP therapy and becomes noticeable 
few months after the first administration [14]. Moreover, 
some retrospective data revealed that occurrence of the 
first SRE before the initiation of BP therapy increased 
the risk of subsequent SREs (HR 2.08) during BP treat-
ment [15]. According to ASCO (American Society of 
Clinical Oncology) experts, it is recommended that BP 
is started in all patients with breast cancer as soon as 
bone metastases are diagnosed [16].
In the Cochrane meta-analysis, the influence of BPs 
on the efficacy of standard systemic treatment of dis-
seminated breast cancer without clinically evident bone 
metastases was evaluated. The results suggest that the 
BPs neither reduced the incidence of bone lesions nor 
improved overall survival (OS) [11].
The role of BPs in the adjuvant setting
Pre-clinical data suggested that BPs may have an 
anti-tumour effect. This is what caused the launch of 
clinical trials with BPs in addition to standard adjuvant 
treatment in prevention of breast cancer recurrence. 
One of the first substances analysed was clodronate. 
Some trials revealed a positive [17, 18], and the other 
a negative [19] impact of clodronate on OS (HR, re-
spectively: 0.38, 0.77, and 1.94). In the most recent trial, 
NSABP B34, which recruited larger numbers of patients, 
clodronate did not reduce the risk of cancer recurrence 
(HR 0.91; 95% Cl 0.78–1.07; p = 0.27) or risk of death 
(HR 0.84; 95% Cl 0.67–1.05; p = 0.13) [20]. In a sub-
group analysis, women over 50 years old treated with BP 
had lower risk of cancer recurrence (HR 0.75; 95% Cl 
0.57–0.99; p = 0.045). Meta-analysis of the trials showed 
that therapy with clodronate did not improve OS (HR 
0.84; 95% Cl 0.56–1.26; p = 0.4), bone metastases-free 
survival (HR 0.77; 95% Cl 0.58–1.02; p = 0.07), or 
extra-skeletal metastases (HR 0.89; 95% Cl 0.61–1.3; 
p = 0.55) [21]. Possibly, the results of the meta-analysis 
were determined by a small (n = 282), negative trial 
carried out by Saarto et al. in the 1990s [19].
The effectiveness of some BPs of the second genera-
tion — ibandronate and pamidronate — in comparison 
to placebo in early breast cancer (node positive or node 
negative) was evaluated in two phase III trials. In the 
GAIN trial with ibandronate there were no differences 
with reference to disease-free survival (DFS) (HR 0.95; 
95% Cl 0.77–1.16; p = 0.59) or OS (HR 1.04; 95% Cl 
0.76–1.42; p = 0.83) [22]. Similarly, in the second trial 
with oral pamidronate, no positive impact on bone recur-
rence-free survival (HR 1,03; 95% CI 0.75–1.4; p = 0.86) 
or on OS (no numbers reported) was observed [23].
The AZURE trial recruited patients with stage II 
or III breast cancer (with or without ER expression). 
A combination of zoledronic acid with a standard 
adjuvant treatment did not influence DFS (HR 0.94; 
95% Cl 0.82–1.06; p = 0.3) or OS (HR 0.93; 95% Cl 
0.81–1.08; p = 0.37) [24]. However, zoledronic acid 
decreased the risk of metastatic bone lesions (HR 0.81; 
95% Cl 0.68–0.97; p = 0.022). An exploratory analysis 
suggested that the positive effect of BP was restricted 
to a cohort of women who passed through menopause 
at least five years before diagnosis (31% of the whole 
trial population). In this subgroup, an improvement in 
invasive disease recurrence-free survival was observed 
(HR 0.77; 95% Cl 0.63–0.96; p = 0.03).
The ABCSG-12 trial was conducted in premenopau-
sal women with early (stage I–II) breast cancer treated 
with ovarian suppression therapy and tamoxifen or 
anastrozole. Concomitant treatment with zoledronic 
acid every six months for three years improved DFS 
(HR 0.77; 95% Cl 0.6–0.99; p = 0.042), while the impact 
on OS was non-significant (HR 0.66; 95% Cl 0.43–1.02; 
p = 0.062) [25]. An important difference between the 
two above-mentioned trials is that in the ABCSG-12 trial 
patients had complete hormonal suppression, so the 
population resembled the postmenopausal subgroup 
form of AZURE. The reduction of disease recurrence 
was similar between the trials (HR 0.77). 
The third trial, ZO-FAST, investigated the role of 
a combination of zoledronic acid and five-year adjuvant 
hormone therapy with letrozole in postmenopausal 
women with breast cancer stage I–III. A control arm 
consisted of hormone therapy, but BPs were intro-
duced in cases of clinical indications (bone fracture, 
bone density loss) [9]. The trial reported a reduction of 
relative risk of disease recurrence by 34% (95% Cl for 
HR: 0.44–0.97; p = 0.037), which did not translate into 
gain in OS (HR 0.69; 95% Cl 0.42–1.14; p = 0.15). An 
explorative analysis suggested that women older than 
60 years or those who passed menopause at least five 
years before diagnosis could benefit in OS (HR 0.5; 
p = 0.022).
To establish the role of adjuvant BPs, an individ-
ual-patient data meta-analysis of 19,000 women with 
early breast cancer involved in 26 clinical trials was 
conducted [26]. It suggests that administration of BPs 
decreased the relative risk of bone recurrence by 17% 
(95% Cl for HR: 0.73–0.94; p = 0.004), and less clearly 
decreased the risk of death (RR 0.91; 95% Cl 0.83–0.99; 
p = 0.04) or risk of distant recurrence (RR 0.92; 95% Cl 
0.85–0.99; p = 0.03). In a subgroup analysis, there were 
no differences in effect irrespective of steroid receptor 
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expression, regional lymph node involvement, or histo-
logical malignancy grade. The benefits of BPs therapy 
may be restricted mainly to women over 55 years or those 
with established menopause. Among postmenopausal 
women, adjuvant BP decreased the relative risk of recur-
rence by 28% (95% Cl for HR: 0.6–0.86; p = 0.0002) 
and relative risk of breast cancer death by 18% (95% 
Cl for HR: 0.73–0.93; p = 0.0002). It was transferred to 
3% of absolute gain in the percentage of patients alive 
after 10 years of follow-up (18% vs. 14.7%).
In the SWOG S0307 trial clodronate, ibandronate, 
and zoledronic acid were investigated in an adjuvant 
setting. No differences between BPs were observed in 
DFS or OS outcomes [27]. There is insufficient evidence 
to recommend alendronate, risedronate, or etidronate 
in the management of early breast cancer. 
According to ESMO (European Society of Medical 
Oncology) recommendations, BPs (clodronate or zole-
dronic acid) should be considered in adjuvant treatment 
of postmenopausal women or in premenopausal women 
with hormonal blockage (aLHRH) [28]. It should be 
mentioned that BPs have no regulatory approval in this 
indication. It is suggested that the therapy be initiated 
simultaneously with standard adjuvant treatment. The 
optimal duration of adjuvant BPs is still unknown, but 
it seems that it should last for 3–5 years, as it was ad-
ministered in trials. In premenopausal women treated 
with aLHRH BPs should accompany only the ablation 
period, unless there are indications to continue BPs 
longer (e.g. low T-score).
BPs in prostate cancer
Prevention of CTIBL
Hormone therapy, both adjuvant and palliative, can 
change bone metabolism in men with prostate cancer. As 
a consequence, men with androgen deprivation therapy 
have higher risk of bone loss. The ESMO recommends 
an assessment of risk of bone-loss before initiation of 
hormone therapy by bone densitometry. Furthermore, 
it is suggested that secondary causes of bone loss be 
evaluated, e.g. serum calcium, parathyroid hormone, 
and 25-OH-vitamin D concentration. Furthermore, it is 
advised that supplementation of calcium (1000 mg/day) 
and vitamin D (1000–2000 IU/day) be initiated, as well 
as moderate exercises, constrained alcohol consump-
tion, and smoking cessation [4]. Anti-resorptives should 
be considered in patients with T-score < –2 or when 
at least two risk factors of osteoporosis occur (e.g. 
age > 65 years, T-score < –1.5, cigarette smoking, 
BMI < 24, long-term steroid intake, bone fractures over 
50 years old, positive family history for osteoporosis) [4]. 
The substances active in this situation are mentioned 
Table 3. Anti-resorptive drugs for the prevention of CTIBL 
in patients with prostate cancer
Bisphosphonates Pamidronate 60 mg i.v. every 12 weeks
Risedronate 35 mg p.o. every week
Alendronate 70 mg p.o. every week
Zoledronic acid 4 mg i.v. every 6 months
Anti-RANKL Denosumab 60 mg s.c. every 6 months
in Table 3. Denosumab is the only anti-resorptive that 
has regulatory approval in this indication. BPs can be 
prescribed only off-label [29–32].
Castration-sensitive prostate cancer with bone 
metastases
The effectiveness of first-generation BP in patients 
with hormone-sensitive prostate cancer with bone 
metastases was investigated in the MRC PR05 trial. 
The primary end-point of the trial was not met — HR 
for symptomatic bone progression-free survival was 
0.79 (p = 0.66). In post-hoc analysis an improvement 
in OS was found — five-year survival rates were higher 
in hormonal therapy with BP group than in the group 
with hormonal therapy alone (30% vs. 21%; R 0.77; 
p = 0.032) [33, 34]. Although the result was statistically 
significant, it did not influence clinical practice, mainly 
due to the character of the mentioned analysis and 
primary positive results with more potent BP — zole-
dronic acid.
The CALGB 90202 study recruited men with pros-
tate cancer with bone metastases, and early initiation of 
zoledronic acid did not reduce the risk of SRE (HR 0.77; 
p = 0.39) compared with such treatment delayed until 
the development of castration resistance [35]. Moreover, 
there was no positive impact of zoledronic acid on PFS 
(HR 0.89; p = 0.22) or OS outcome (HR 0.88; p = 0.29).
In the STAMPEDE trial, one of several arms of 
treatment evaluated the efficacy of zoledronic acid in 
men with hormone-sensitive prostate cancer undergoing 
standard hormonal treatment. There were no differ-
ences in OS (HR 0.94; p = 0.45), failure-free survival 
(HR 0.92; p = 0.2), or time to SRE (HR 0.89; p = 0.22) 
compared with hormonal therapy alone. The BP did not 
influence prognosis also in the metastatic subgroup [36]. 
In another arm of the trial a combination of hormonal 
therapy, docetaxel, and zoledronic acid was evaluated. 
The efficacy of the combination therapy did not differ 
from hormonal therapy plus docetaxel (HR for OS 
1.06; p = 0.59).
A meta-analysis of trials with BPs in castration-sen-
sitive prostate cancer was published in 2016. Its results 
suggested an improvement in OS (HR 0.88; 95% Cl 
0.79–0.98; p = 0.025) among men with metastatic dis-
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ease with an increase in four-year survival rate by 5%. 
After excluding data from the MRC PR05 trial with clo-
dronate, the effect became insignificant (HR 0.94; 95% 
Cl 0.83–1.07; p = 0.32) [37]. In a subgroup of patients 
with locally advanced disease, meta-analysis did not show 
any difference in OS in patients treated with clodronate 
(HR 1,03; 95% Cl 0,89–1,18; p = 0,72) or with zoledronic 
acid (HR 0.98; 95% Cl 0.82–1.16; p = 0.78).
Castration-resistant prostate cancer (CRPC)
There are no data supporting the use of zoledronic 
acid in locally advanced CRPC — the ZOMETA 
704 trial was terminated early because of low event rates 
(smaller than expected).
In phase III trials in bone-metastatic CRPC neither 
pamidronate nor clodronate proved to be more effec-
tive than placebo in cases of bone pain or SRE [38, 39]. 
Higher activity of zoledronic acid in patients with 
CRPC and bone metastases was demonstrated in the ZO-
META 039 trial and led to the registration of the only BP 
in this indication. Therapy with zoledronic acid (4 mg every 
three weeks) compared to placebo was more effective in 
reduction of SRE rate after 24 months of treatment. The 
proportion of patients with at least one SRE was 38% in 
the group of patients treated with zoledronic acid and 
49% in the control group (p = 0.028). Median time to 
first SRE was increased (by approximately six months) 
in the BP arm (HR 0.68; p = 0.009), and the cumulative 
risk of SRE was reduced (HR 0.68; 95% Cl 0.49–0.84; 
p = 0.002) [40]. The benefits of BP did not translate into 
risk of progression or quality of life. An analgesic effect 
was observed only in patients who had initiated the treat-
ment with 8 mg of zoledronic acid (p = 0.026) [41].
BPs were evaluated also in an adjuvant setting after 
local treatment of prostate cancer. Neither clodronate 
(MRC PR 04 trial) nor zoledronic acid (ZEUS trial) 
decreased the risk of bone metastases [22–42]. 
In conclusion, there are several applications of BPs 
in prostate cancer:
 — reduction of risk of SRE in men with CRPC and 
bone metastases (zoledronic acid);
 — decrease of risk of CTIBL in men with risk factors 
of osteoporosis undergoing palliative or adjuvant 
hormonal therapy.
It should be emphasised that there are no data 
supporting the use of BPs in the prevention of SRE in 
men with prostate cancer and bone metastases before 
development of CRPC.
Dosage of BPs in cancer patients with bone 
metastases
The proper dosage of clodronate (1600 mg orally 
every day) and pamidronate (90 mg in a two-hour infu-
sion every 3–4 weeks) in women with metastatic breast 
cancer was established in clinical trials.
Zoledronic acid (4 mg in a 15-min. infusion) should 
be administered every 3–4 weeks in patients with 
bone-metastatic cancer. The results of two randomised 
clinical trials comparing standard dose of zoledronic 
acid with a regimen with longer intervals were pub-
lished in 2017. Zoledronic acid (4 mg) every 12 weeks 
was as effective as the BP every four weeks with regard 
to reduction of the risk of SRE in patients with breast 
cancer, prostate cancer, and multiple myeloma [45, 46].
Summary
Bisphosphonates in the treatment of patients with 
cancer are used for three main reasons. The most in-
triguing one is their antineoplastic activity. However, the 
efficacy of BPs in this setting is limited to patients with 
early breast cancer after menopause or those receiving 
inhibition of ovary function — adjuvant BPs reduce the 
risk of recurrence and improve survival. The second 
and best-known reason is to decrease of symptoms or 
signs related to cancer, e.g. pain, hypercalcaemia, and 
SRE — the most significant data regarding SRE were 
collected in patients with breast, prostate cancer, and 
multiple myeloma. The third purpose of therapy is 
prevention or alleviation of cancer treatment-related 
adverse effects — it is documented in clinical trials that 
BPs administered in women with breast cancer, and also 
in men with prostate cancer, decrease the risk of CTIBL 
in the course of hormonal therapy.
BPs are generally well tolerated drugs, but some side 
effects are typical for the class. The most important ad-
verse events are: reactions of acute phase (up to 25–30% 
in patients who receive intravenous infusions), exacerba-
tion of bone pain, hypocalcaemia, kidney insufficiency 
(BPs should be administered with caution if creatinine 
clearance is < 30 ml/min), acute osteonecrosis of the jaw 
(up to 1.5% of patients who receive BPs intravenously), 
atypical femoral fractures, and gastrointestinal disorders 
(mostly after oral BPs).
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